Sublingual five-grass pollen tablets (Oralair®): a guide to their use as allergen immunotherapy for grass pollen-induced allergic rhinoconjunctivitis

[1]  G. Dranitsaris,et al.  Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost. , 2014, Journal of evaluation in clinical practice.

[2]  R. Pawankar,et al.  Allergic rhinitis: current options and future perspectives , 2014, Current opinion in allergy and clinical immunology.

[3]  J. Bousquet,et al.  Sublingual immunotherapy: World Allergy Organization position paper 2013 update , 2014, The World Allergy Organization journal.

[4]  R. Mösges,et al.  PD14 - Non-interventional 2-year study of sublingual immunotherapy in children and adolescents with allergic rhinoconjunctivitis caused by grass pollen , 2014, Clinical and Translational Allergy.

[5]  R. Mösges,et al.  P85 - Asthmatic children and adolescents treated in daily medical practice – results from a 2-year sublingual allergen immunotherapy (AIT) study with grass pollen tablets , 2014, Clinical and Translational Allergy.

[6]  L. Losappio,et al.  5-grass pollen tablets achieve disease control in patients with seasonal allergic rhinitis unresponsive to drugs: a real-life study , 2013, Journal of asthma and allergy.

[7]  H. Malling,et al.  Post‐treatment efficacy of discontinuous treatment with 300IR 5‐grass pollen sublingual tablet in adults with grass pollen‐induced allergic rhinoconjunctivitis , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[8]  T. Casale,et al.  Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. , 2013, The Journal of allergy and clinical immunology.

[9]  A. Cicchetti,et al.  Economic Evaluation of 5-Grass Pollen Tablets Versus Placebo in the Treatment of Allergic Rhinitis in Adults , 2013, Clinical Drug Investigation.

[10]  L. Klimek,et al.  Specific immunotherapy-indications and mode of action. , 2013, Deutsches Arzteblatt international.

[11]  T. Casale,et al.  Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. , 2012, The Journal of allergy and clinical immunology.

[12]  M. Augustin,et al.  Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany , 2012, Journal of medical economics.

[13]  H. Malling,et al.  Post-treatment, Long-term Efficacy Of A 300IR Sublingual Tablet Of 5-grass Pollen Allergen Extract In Adults With Grass Pollen-induced Allergic Rhinoconjunctivitis: The Relationship With Disease Severity , 2012 .

[14]  A. Iglesias-Cadarso,et al.  Risk factors for systemic reactions to allergen immunotherapy , 2011, Current opinion in allergy and clinical immunology.

[15]  C. Rhee,et al.  Sublingual immunotherapy in allergic rhinitis , 2011, Asia Pacific allergy.

[16]  H. Malling,et al.  Rhinitis , sinusitis , and upper airway disease Sustained 3-year efficacy of pre-and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen – induced rhinoconjunctivitis , 2011 .

[17]  E. Vicaut,et al.  The average Adjusted Symptom Score, a new primary efficacy end‐point for specific allergen immunotherapy trials , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[18]  P. Devillier,et al.  The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy , 2011, Allergy.

[19]  J. Bousquet,et al.  GA2LEN/EAACI pocket guide for allergen‐specific immunotherapy for allergic rhinitis and asthma , 2010, Allergy.

[20]  S. Halken,et al.  Five‐grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents , 2010, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[21]  Holger J Schünemann,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. , 2010, The Journal of allergy and clinical immunology.

[22]  P. Devillier,et al.  Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. , 2009, The Journal of allergy and clinical immunology.

[23]  A. Didier,et al.  Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[24]  H. Malling,et al.  Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[25]  A. Didier,et al.  Agreement of efficacy assessments for five‐grass pollen sublingual tablet immunotherapy , 2009, Allergy.

[26]  H. Malling,et al.  Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. , 2007, The Journal of allergy and clinical immunology.

[27]  J Bousquet,et al.  Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce , 2007, Allergy.

[28]  P. Kuna,et al.  Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. , 2009, The Journal of allergy and clinical immunology.